spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hyperuricemia 

 HSMN NewsFeed - 24 Jan 2024
ZWI Therapeutics, Inc. Announces a Series A Financing, Two Accomplished Biopharmaceutical CEOs Join the Board of Directors, and Appointment of Chief Executive Officer
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 May 2013
Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE(R) (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Oct 2012
Savient Receives Positive CHMP Opinion for KRYSTEXXA(R) Approval in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Jun 2012
AstraZeneca Completes Acquisition of Ardea Biosciences
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2012
Savient Announces Named Patient Programme for KRYSTEXXA(R) in the European Union for Patients with Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2012
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 3 Nov 2011
Savient Pharmaceuticals Receives J-code for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 13 May 2011
Teijin Pharma to Launch Feburic(r) (febuxostat) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Jan 2011
Savient Pharmaceuticals Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2010
FDA Approves New Drug Application for PANCREAZE(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Apr 2010
Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2009
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2009
Eurand Granted FDA Approval for ZENPEP(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2009
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals
 HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Feb 2008
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2007
Solvay Pharmaceuticals, Inc. Receives Approvable Letter from FDA with Respect to New Drug Application for CREON(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
hyperuricemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.